Search articles in News

Filter Articles

Open filters

Sections

Found 2,566 articles

Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
- 2 Apr 2024
- Editor
Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software.
Voydeya approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular haemolysis in adults with the rare disease PNH
- 2 Apr 2024
- Editor
Voydeya (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH).1
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
- 2 Apr 2024
- Editor
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease.
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
- 2 Apr 2024
- Editor
Moderna, Inc. (NASDAQ:MRNA) today announced at its fifth Vaccines Day event clinical and program updates demonstrating advancement and acceleration of its mRNA pipeline. The updates include data readouts in the Company's respiratory and latent and other vaccine portfolios, as well as commercial, manufacturing and financial announcements for its vaccines business.
Caidya Expands Global Presence with the Establishment of Caidya Canada Limited and New Office in Toronto
- 2 Apr 2024
- Editor
Caidya, a leading global, multi-therapeutic clinical research organization (CRO), is pleased to announce the establishment of its new legal entity, Caidya Canada Limited, and the opening of its new office in Toronto, Ontario.
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
- 28 Mar 2024
- Editor
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Lucie Larguier as Chief Financial Officer (CFO), effective immediately.
Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team
- 26 Mar 2024
- PharmiWeb Editor
Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director.
Cambridge Cognition announces formation of new Scientific Advisory Board
- 21 Mar 2024
- PharmiWeb Editor
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board.
BioPharma Companies Recognised in 2024 UK’s Best Workplaces™ List
- 21 Mar 2024
- PharmiWeb Editor
Employees from top biopharma companies such as AbbVie, AXON and Aspire Scientific are amongst the 250,000 UK personnel who surveyed with Great Place To Work® UK. Using the data gathered from the research-backed and anonymous employee experience surveys, Great Place To Work has announced its annual UK’s Best Workplaces™ list.
Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
- 20 Mar 2024
Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.
CHARAC ACQUIRES LEADING PRESCRIPTION DELIVERY MANAGEMENT SYSTEM PDM
- 20 Mar 2024
- PharmiWeb Editor
Charac, a leading healthcare SaaS provider, today announces the acquisition of Pro Delivery Manager (PDM), a leading prescription delivery management system, from its shareholders, which include the National Pharmacy Association (NPA).
Rise in BME and disabled leaders encouraging but challenges remain
- 20 Mar 2024
Responding to the publication of NHS Workforce Race Equality Standard (WRES) and Workforce Disability Equality Standard (WDES) Joan Saddler, director of partnerships and equality at the NHS Confederation...
Global Life Science Agency Appoints Chief Financial Officer
- 20 Mar 2024
- PharmiWeb Editor
International specialist marketing and commercial growth agency, ramarketing has announced a senior leadership appointment as it continues to expand globally.
Seqera appoints Melinda Pautsch as Chief Revenue Officer
- 20 Mar 2024
- PharmiWeb Editor
Seqera, the leading software provider for data analysis in the life sciences space, today announced the appointment of Melinda Pautsch as its Chief Revenue Officer (CRO). The appointment marks a significant step in the company's growth journey, as it focuses on strengthening its market position as the open science platform of choice and delivering value for customers across the Nextflow ecosystem.
China unveils ChatGPT-like medical chatbot service
- 20 Mar 2024
- PharmiWeb Editor
Hong Kong-based Centre for Artificial Intelligence and Robotics (CAIR) under the Chinese Academy of Sciences (CAS), one of China's national research institutes, has developed a large language model-based chatbot to assist doctors in making medical diagnoses and treatments.
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
- 14 Mar 2024
- Editor
Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP).
AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline
- 14 Mar 2024
- Editor
AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.
New AI model detects ninety percent of lymphatic cancer cases
- 14 Mar 2024
- PharmiWeb Editor
Medical image analysis using AI has developed rapidly in recent years. Now, one of the largest studies to date has been carried out using AI-assisted image analysis of lymphoma, cancer of the lymphatic system. Researchers at Chalmers University of Technology in Sweden, have developed a computer model that can successfully find signs of lymph node cancer in 90 percent of cases.
What do Clinical Research Organisations Do?
- 13 Mar 2024
- Lucy Walters
Clinical Research Organisations (CROs) play a crucial role in advancing medical knowledge and therapeutic innovations. As vital intermediaries between pharmaceutical and biotechnology companies, healthcare professionals, and regulatory bodies, CROs help facilitate the clinical development of new drugs, devices, and treatments.
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL ® 9
- 13 Mar 2024
- Editor
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types.